January 18, 2022 -- Illumina's CEO, Francis deSouza, discussed the company's growth trajectory, including 2021 results and 2022 guidance at the 2022 virtual J.P Morgan Healthcare Conference. The company also announced new partnerships and technologies to advance its mission of improving human health by unlocking the power of the genome.
Illumina delivered a strong finish to 2021, with preliminary consolidated fourth quarter revenue of approximately $1.19 billion, up 25% year over year. Illumina also delivered a preliminary fiscal year 2021 consolidated revenue of approximately $4.517 billion, up 39% year over year. The company expects another strong year in 2022.
Illumina has formed new collaborations with Agendia, Boehringer Ingelheim, Optum, and Nashville Biosciences to accelerate access, utilization, and discovery for genomics, deSouza said.
Copyright © 2022 scienceboard.net